Zacks Investment Research upgraded shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) from a sell rating to a hold rating in a research note published on Tuesday, August 29th.
According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
AIMT has been the topic of a number of other reports. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the stock a buy rating in a report on Thursday, July 27th. ValuEngine cut shares of Aimmune Therapeutics from a hold rating to a sell rating in a report on Saturday, May 27th. Wedbush restated an ourperform rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a report on Monday, August 14th. Finally, BidaskClub cut shares of Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $32.50.
Shares of Aimmune Therapeutics (NASDAQ AIMT) traded up 2.14% during trading on Tuesday, hitting $23.86. The stock had a trading volume of 134,898 shares. The firm has a 50-day moving average of $23.17 and a 200 day moving average of $21.15. Aimmune Therapeutics has a 1-year low of $14.11 and a 1-year high of $27.31. The company’s market capitalization is $1.21 billion.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Equities research analysts predict that Aimmune Therapeutics will post ($2.71) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://stocknewstimes.com/2017/09/13/aimmune-therapeutics-inc-aimt-upgraded-to-hold-at-zacks-investment-research.html.
In related news, insider Susan E. Barrowcliffe sold 15,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $20.26, for a total value of $303,900.00. Following the completion of the transaction, the insider now directly owns 15,000 shares of the company’s stock, valued at approximately $303,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen George Dilly sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total transaction of $1,073,000.00. The disclosure for this sale can be found here. Insiders sold a total of 236,860 shares of company stock worth $5,021,672 over the last 90 days. Company insiders own 24.56% of the company’s stock.
Large investors have recently bought and sold shares of the company. SG Americas Securities LLC increased its holdings in shares of Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 499 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Aimmune Therapeutics by 454.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 4,900 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 1,634 shares in the last quarter. Voya Investment Management LLC increased its holdings in shares of Aimmune Therapeutics by 31.2% during the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 3,757 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Aimmune Therapeutics in the 2nd quarter valued at $333,000. 72.90% of the stock is owned by hedge funds and other institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.